Flanagan W. Michael — SEC insider filings
SEC reporting owner CIK 1841990. 23 insider filings on record with FilingPulse; latest filed 2026-09-22.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2021-01-25 to 2026-09-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 14 filings — 336,230 shares, $13,498,776 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: sale of 62,500 shares @ $47.62 ($2,976,112) in Avidity Biosciences, Inc., filed 2024-10-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. (RNAM) | Chief Scientific Officer | 21 | — | 19 legs · 336,230 sh · $13,498,776 | 36 |
| Atrium Therapeutics, Inc. (RNA) | Director | 2 | — | — | 2 |
Insider filings — Flanagan W. Michael
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-22 | 4 | Atrium Therapeutics, Inc. (RNA) | Tax withholding (F): 22,812 @ $8.95 | EDGAR |
| 2026-03-02 | 4 | Atrium Therapeutics, Inc. (RNA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Avidity Biosciences, Inc. (RNAM) | Disposition to issuer (D): 150,365 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 66,500 (derivative) · Disposition to issuer (D): 96,000 (derivative) · Disposition to issuer (D): 72,000 (derivative) · Disposition to issuer (D): 88,000 (derivative) · +1 more | EDGAR |
| 2026-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 3,976 @ $72.45 · Sale (S): 2,558 @ $72.45 | EDGAR |
| 2026-01-09 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 2,373 @ $72.23 | EDGAR |
| 2025-12-19 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 27,500 @ $0 · Tax withholding (F): 13,695 @ $71.87 | EDGAR |
| 2025-09-12 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 20,000 @ $14.22 · Sale (S): 20,000 @ $38.94 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 20,000 @ $14.22 · Sale (S): 20,000 @ $32.88 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 11,780 @ $31.06 | EDGAR |
| 2025-03-12 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 20,000 @ $14.22 · Sale (S): 20,000 @ $30.13 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 3,860 @ $28.60 · Sale (S): 1,812 @ $28.59 | EDGAR |
| 2025-01-08 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 12,742 @ $32.66 | EDGAR |
| 2024-12-13 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 24,000 @ $22.47 · Sale (S): 24,000 @ $35.77 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 62,500 @ $26.75 · Sale (S): 62,500 @ $47.62 · Option exercise (M): 62,500 (derivative) @ $0 | EDGAR |
| 2024-09-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Sale (S): 13,153 @ $44.00 · Grant/award (A): 25,000 @ $0 · Sale (S): 11,847 @ $43.89 | EDGAR |
| 2024-09-13 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 62,500 @ $26.75 · Sale (S): 62,500 @ $40.40 · Option exercise (M): 34,000 @ $22.47 · Sale (S): 34,000 @ $40.40 · Sale (S): 14,894 @ $40.40 · Option exercise (M): 62,500 (derivative) @ $0 · +1 more | EDGAR |
| 2024-06-20 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Sale (S): 10,106 @ $39.13 · Grant/award (A): 25,000 @ $0 | EDGAR |
| 2024-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 20,000 @ $0 · Sale (S): 4,129 @ $10.13 · Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2023-09-12 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 144,000 (derivative) @ $0 | EDGAR |
| 2022-03-15 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 136,500 (derivative) @ $0 | EDGAR |
| 2021-01-25 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1841990 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs